ロード中...
Phase 1 study of a bispecific ligand-directed toxin targeting CD22 and CD19 (DT2219) for refractory B-cell malignancies
BACKGROUND: The novel bispecific ligand-directed toxin (BLT) DT2219 consists of a recombinant fusion between the catalytic and translocation enhancing domain of diphtheria toxin (DT) and bispecific single chain variable fragments (scFV) of antibodies targeting human CD19 and CD22. We conducted a pha...
保存先:
| 出版年: | Clin Cancer Res |
|---|---|
| 主要な著者: | , , , , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2015
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4360883/ https://ncbi.nlm.nih.gov/pubmed/25770294 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-14-2877 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|